ERBB2 and breast cancer: Moreover, our in vitro and in vivo results identified a breast cancer sub-group (HER-2 IHC 1+ / 2+ and FISH negative with high frequency of HER-1:HER-3 heterodimer) that might benefit from HER-3 selective targeting agents, irrespectively of HRG1 expression.